Loading...
•
Mar 31, 2023
NextCure Q1 2023 Earnings Report
NextCure's financial position decreased, with a net loss, but remained optimistic about pipeline advancement and clinical milestones.
Key Takeaways
NextCure reported its Q1 2023 financial results, including a net loss of $16.1 million, and R&D expenses of $11.6 million. The company's cash, cash equivalents, and marketable securities were $145.5 million as of March 31, 2023, expected to fund operations into mid-2025. Clinical data readouts are expected in 2023 for NC410, NC762, and NC525 programs.
Cash, cash equivalents, and marketable securities totaled $145.5 million on March 31, 2023.
The first patient was dosed with NC525 in a Phase 1 trial for acute myeloid leukemia (AML).
Net loss for the quarter was $16.1 million.
The company expects to fund operations into mid-2025 with current cash reserves.
NextCure
NextCure
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.